Correction to: Long-term health-related quality of\xa0life in\xa0patients treated with\xa0subcutaneous C1-inhibitor replacement therapy for\xa0the\xa0prevention of\xa0hereditary angioedema attacks: findings from\xa0the\xa0COMPACT open-label extension study

Bruce L. Zuraw ,Subhransu Prusty,J. Anderson ,Hilary Longhurst,Richard Gower ,Thomas Machnig,Henriette Farkas,Jonathan A. Bernstein,Teresa Caballero,H. Henry Li,Aleena Banerji,Paul K. Keith,Donald S. Levy,William R. Lumry,John‐Philip Lawo ,Marc A. Riedl,Markus Magerl,Timothy J. Craig ,Marco Cicardi,M. A. Manning ,Null Author_Id

doi:10.1186/s13023-021-01975-2

Abstract

Correction to: Long-term health-related quality of\xa0life in\xa0patients treated with\xa0subcutaneous C1-inhibitor replacement therapy for\xa0the\xa0prevention of\xa0hereditary angioedema attacks: findings from\xa0the\xa0COMPACT open-label extension study

Highlights

Correction to: Long‐term health‐related quality of life in patients treated with subcutaneous C1‐inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open‐label extension study
Following the publication of the original article [1] the authors informed us of an error in the second paragraph under ‘Study population’ of the ‘Results’ section
An additional 15 patients (11.9%) were using other forms of HAE prophylaxis] or oral danazol) within the 3-month period prior to the open-label study”

Summary

Introduction

Following the publication of the original article [1] the authors informed us of an error in the second paragraph under ‘Study population’ of the ‘Results’ section. Correction to: Long‐term health‐related quality of life in patients treated with subcutaneous C1‐inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open‐label extension study Correction to: Orphanet J Rare Dis (2021) 16:86 https://doi.org/10.1186/s13023-020-01658-4 The paragraph should read: “Half of the patients in the study (n = 64, 50.8%) were participants in the double-blind COMPACT study, were using C1-INH(SC) prophylaxis prior to continuing into the open-label study (Table 1). An additional 15 patients (11.9%) were using other forms of HAE prophylaxis (intravenous C1-INH [C1-INH[IV)] or oral danazol) within the 3-month period prior to the open-label study”.

Results

Conclusion